IDEAS home Printed from https://ideas.repec.org/a/spr/patien/v12y2019i4d10.1007_s40271-019-00358-x.html
   My bibliography  Save this article

Measuring the Burden of Schizophrenia Using Clinician and Patient-Reported Measures: An Exploratory Analysis of Construct Validity

Author

Listed:
  • Matthew Franklin

    (Health Economics and Decision Science (HEDS), School of Health and Related Research (ScHARR), University of Sheffield)

  • Clara Mukuria

    (Health Economics and Decision Science (HEDS), School of Health and Related Research (ScHARR), University of Sheffield)

  • Brendan Mulhern

    (Health Economics and Decision Science (HEDS), School of Health and Related Research (ScHARR), University of Sheffield
    University of Technology Sydney)

  • Irwin Tran

    (Health Economics and Strategic Pricing, Roche Products Limited)

  • John Brazier

    (Health Economics and Decision Science (HEDS), School of Health and Related Research (ScHARR), University of Sheffield)

  • Stuart Watson

    (Newcastle University
    Northumberland Tyne and Wear NHS Foundation Trust)

Abstract

Background Various self-reported or clinician-reported (as a proxy) measures exist to quantify the burden of schizophrenia on patients. Evidence of the psychometric relationship between these measures to inform their practical use is limited. Objectives Our objective was to conduct an exploratory analysis of the construct validity of patient-reported (EQ-5D, SF-6D, WEMWBS, SQLS subscales of Psychosocial, Motivation, Symptoms) versus clinician-reported measures (PANSS, CGI-SCH, NSA-4, HoNOS-PbR) to inform future use of patient-reported measures for burden-of-illness assessment and/or economic evaluation. Methods In an adult patient population with schizophrenia, construct validity was assessed in relation to convergent and known-group validity. Convergent validity was assessed using Spearman’s rank absolute correlation strength (ACS: weak ≤ 0.3, moderate = 0.3

Suggested Citation

  • Matthew Franklin & Clara Mukuria & Brendan Mulhern & Irwin Tran & John Brazier & Stuart Watson, 2019. "Measuring the Burden of Schizophrenia Using Clinician and Patient-Reported Measures: An Exploratory Analysis of Construct Validity," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 12(4), pages 405-417, August.
    • Handle: RePEc:spr:patien:v:12:y:2019:i:4:d:10.1007_s40271-019-00358-x
    DOI: 10.1007/s40271-019-00358-x
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40271-019-00358-x
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40271-019-00358-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Rowena Jacobs, 2009. "Investigating Patient Outcome Measures in Mental Health," Working Papers 048cherp, Centre for Health Economics, University of York.
    2. John Brazier & Jennifer Roberts & Aki Tsuchiya & Jan Busschbach, 2004. "A comparison of the EQ‐5D and SF‐6D across seven patient groups," Health Economics, John Wiley & Sons, Ltd., vol. 13(9), pages 873-884, September.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Brazier, JE & Yang, Y & Tsuchiya, A, 2008. "A review of studies mapping (or cross walking) from non-preference based measures of health to generic preference-based measures," MPRA Paper 29808, University Library of Munich, Germany.
    2. Hirsch Ruchlin & Ralph Insinga, 2008. "A Review of Health-Utility Data for Osteoarthritis," PharmacoEconomics, Springer, vol. 26(11), pages 925-935, November.
    3. Marco DiBonaventura & Lance Richard & Maya Kumar & Anna Forsythe & Natalia M Flores & Margaret Moline, 2015. "The Association between Insomnia and Insomnia Treatment Side Effects on Health Status, Work Productivity, and Healthcare Resource Use," PLOS ONE, Public Library of Science, vol. 10(10), pages 1-14, October.
    4. Efthymiadou, Olina & Mossman, Jean & Kanavos, Panos, 2019. "Health related quality of life aspects not captured by EQ-5D-5L: Results from an international survey of patients," Health Policy, Elsevier, vol. 123(2), pages 159-165.
    5. C. Rubio-Terrés & J. Soria & P. Morange & J. Souto & P. Suchon & J. Mateo & N. Saut & D. Rubio-Rodríguez & J. Sala & A. Gracia & S. Pich & E. Salas, 2015. "Economic Analysis of Thrombo inCode, a Clinical–Genetic Function for Assessing the Risk of Venous Thromboembolism," Applied Health Economics and Health Policy, Springer, vol. 13(2), pages 233-242, April.
    6. D. Stratmann‐Schoene & T. Kuehn & R. Kreienberg & R. Leidl, 2006. "A preference‐based index for the SF‐12," Health Economics, John Wiley & Sons, Ltd., vol. 15(6), pages 553-564, June.
    7. Stavros Petrou & Christine Hockley, 2005. "An investigation into the empirical validity of the EQ‐5D and SF‐6D based on hypothetical preferences in a general population," Health Economics, John Wiley & Sons, Ltd., vol. 14(11), pages 1169-1189, November.
    8. Nalin Payakachat & Mir Ali & J. Tilford, 2015. "Can The EQ-5D Detect Meaningful Change? A Systematic Review," PharmacoEconomics, Springer, vol. 33(11), pages 1137-1154, November.
    9. Garry Barton & Tracey Sach & Michael Doherty & Anthony Avery & Claire Jenkinson & Kenneth Muir, 2008. "An assessment of the discriminative ability of the EQ-5D index , SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(3), pages 237-249, August.
    10. Bruno Casal & Eva Rodríguez-Míguez & Berta Rivera, 2020. "Measuring intangible cost-of-morbidity due to substance dependence: implications of using alternative preference-based instruments," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 1039-1048, September.
    11. Roberta Ara & John Brazier & Ismail Azzabi Zouraq, 2017. "The Use of Health State Utility Values in Decision Models," PharmacoEconomics, Springer, vol. 35(1), pages 77-88, December.
    12. Julie A. Campbell & Andrew J. Palmer & Alison Venn & Melanie Sharman & Petr Otahal & Amanda Neil, 2016. "A Head-to-Head Comparison of the EQ-5D-5L and AQoL-8D Multi-Attribute Utility Instruments in Patients Who Have Previously Undergone Bariatric Surgery," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 9(4), pages 311-322, August.
    13. Clare C. Brown & J. Mick Tilford & Nalin Payakachat & D. Keith Williams & Karen A. Kuhlthau & Jeffrey M. Pyne & Renske J. Hoefman & Werner B. F. Brouwer, 2019. "Measuring Health Spillover Effects in Caregivers of Children with Autism Spectrum Disorder: A Comparison of the EQ-5D-3L and SF-6D," PharmacoEconomics, Springer, vol. 37(4), pages 609-620, April.
    14. Richard Grieve & Marina Grishchenko & John Cairns, 2009. "SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(1), pages 15-23, February.
    15. Aureliano Paolo Finch & John Edward Brazier & Clara Mukuria, 2018. "What is the evidence for the performance of generic preference-based measures? A systematic overview of reviews," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 557-570, May.
    16. Garry R. Barton & Tracey H. Sach & Anthony J. Avery & Claire Jenkinson & Michael Doherty & David K. Whynes & Kenneth R. Muir, 2008. "A comparison of the performance of the EQ‐5D and SF‐6D for individuals aged ≥ 45 years," Health Economics, John Wiley & Sons, Ltd., vol. 17(7), pages 815-832, July.
    17. Raymond Oppong & Billingsley Kaambwa & Jacqueline Nuttall & Kerenza Hood & Richard Smith & Joanna Coast, 2013. "The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(2), pages 197-209, April.
    18. Finch, Aureliano Paolo & Mulhern, Brendan, 2022. "Where do measures of health, social care and wellbeing fit within a wider measurement framework? Implications for the measurement of quality of life and the identification of bolt-ons," Social Science & Medicine, Elsevier, vol. 313(C).
    19. Alan Brennan & Roberta Ara & Raimund Sterz & Bernd Matiba & Rito Bergemann, 2006. "Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(4), pages 276-284, December.
    20. Yaling Yang & John Brazier & Louise Longworth, 2015. "EQ-5D in skin conditions: an assessment of validity and responsiveness," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 927-939, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:patien:v:12:y:2019:i:4:d:10.1007_s40271-019-00358-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.